Analytical Data
-
Gene name
DOCK2
- Application
-
Alternative Names
DOCK2；KIAA0209；Dedicator of cytokinesis Protein 2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q92608
-
Expression Region
全长
-
AA Sequence
full
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DOCK2 (Dedicator of Cytokinesis 2) is a member of the DOCK family of guanine nucleotide exchange factors (GEFs) that play crucial roles in the regulation of actin cytoskeleton dynamics and cell motility. Research on DOCK2 has gained significant interest due to its essential function in various immune responses, particularly in lymphocyte development and migration. DOCK2 facilitates the activation of Rac small GTPases, which are key regulators of cytoskeletal rearrangements essential for cell migration, adhesion, and polarization. Deficiencies in DOCK2 function have been linked to immunodeficiencies, as seen in patients exhibiting severe combined immunodeficiency (SCID) due to mutations in the DOCK2 gene. Moreover, DOCK2 has implications in various diseases, including cancer metastasis and autoimmune disorders, where aberrant cell migration plays a critical role. To better understand its biological functions and therapeutic potential, researchers have focused on the production and characterization of recombinant DOCK2 proteins. These studies aim to elucidate DOCK2's molecular mechanisms, including its interaction with other cellular proteins and its regulation by different signaling pathways. The generation of purified DOCK2 proteins allows for detailed biophysical analyses and functional assays, which are crucial for exploring the potential of targeting DOCK2-related pathways in disease treatment. Overall, the investigation of DOCK2 recombinants not only enhances our fundamental understanding of immune cell dynamics but also opens avenues for novel therapeutic strategies that could modulate immune responses in various pathologies.
